Susquehanna International Group LLP bought a new position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 14,828 shares of the company’s stock, valued at approximately $36,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in TRVI. WealthTrust Axiom LLC purchased a new stake in shares of Trevi Therapeutics in the fourth quarter worth $27,000. Canada Pension Plan Investment Board purchased a new stake in shares of Trevi Therapeutics in the fourth quarter worth $36,000. Finally, Renaissance Technologies LLC purchased a new stake in shares of Trevi Therapeutics in the fourth quarter worth $62,000. 72.16% of the stock is currently owned by hedge funds and other institutional investors.

Separately, Zacks Investment Research cut Trevi Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 13th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $9.40.

Trevi Therapeutics stock opened at $2.25 on Wednesday. The company has a debt-to-equity ratio of 0.39, a current ratio of 9.05 and a quick ratio of 9.05. Trevi Therapeutics, Inc. has a one year low of $2.13 and a one year high of $8.50. The stock has a market capitalization of $44.81 million, a PE ratio of -1.51 and a beta of 0.10. The business’s fifty day moving average is $2.66 and its 200 day moving average is $3.02.

Trevi Therapeutics Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease, as well as to treat chronic kidney disease-associated with pruritus.

Featured Article: How accurate is the Rule of 72?

Want to see what other hedge funds are holding TRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Trevi Therapeutics, Inc. (NASDAQ:TRVI).

Institutional Ownership by Quarter for Trevi Therapeutics (NASDAQ:TRVI)

Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.